Nova Mentis Life Science Corp. (NMLSF)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -8088.00 CAD | 96.97% |
| 2022 | -266.51 Thousand CAD | -21.85% |
| 2021 | -218.73 Thousand CAD | 89.76% |
| 2020 | -2.13 Million CAD | -2354.22% |
| 2019 | -87 Thousand CAD | 78.38% |
| 2018 | -402.39 Thousand CAD | 66.77% |
| 2017 | -1.21 Million CAD | -85.08% |
| 2016 | -654.34 Thousand CAD | -288.45% |
| 2015 | -168.45 Thousand CAD | -87.16% |
| 2014 | -90 Thousand CAD | -5574.91% |
| 2013 | -1586.00 CAD | 45.18% |
| 2012 | -2893.00 CAD | 98.86% |
| 2011 | -253.79 Thousand CAD | 8.11% |
| 2010 | -276.19 Thousand CAD | -27.79% |
| 2009 | -216.13 Thousand CAD | 38.72% |
| 2008 | -352.69 Thousand CAD | -94.48% |
| 2007 | -181.34 Thousand CAD | 23.58% |
| 2006 | -237.29 Thousand CAD | -476.38% |
| 2005 | -41.17 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 38.17 Thousand CAD | 572.05% |
| 2024 Q2 | 47.94 Thousand CAD | 25.57% |
| 2023 FY | -8088.00 CAD | 96.97% |
| 2023 Q3 | -24.44 Thousand CAD | -40.13% |
| 2023 Q1 | -113.94 Thousand CAD | 57.25% |
| 2023 Q4 | -8088.00 CAD | 66.91% |
| 2023 Q2 | -17.44 Thousand CAD | 84.69% |
| 2022 Q3 | -461.95 Thousand CAD | 27.18% |
| 2022 FY | -266.51 Thousand CAD | -21.85% |
| 2022 Q1 | -1.12 Million CAD | -416.52% |
| 2022 Q2 | -634.35 Thousand CAD | 43.85% |
| 2022 Q4 | -266.51 Thousand CAD | 42.31% |
| 2021 Q1 | -1.5 Million CAD | 29.48% |
| 2021 Q2 | -1.12 Million CAD | 25.52% |
| 2021 Q3 | -767.18 Thousand CAD | 31.59% |
| 2021 Q4 | -218.73 Thousand CAD | 71.49% |
| 2021 FY | -218.73 Thousand CAD | 89.76% |
| 2020 Q1 | -73.46 Thousand CAD | 15.57% |
| 2020 Q4 | -2.13 Million CAD | -636.49% |
| 2020 FY | -2.13 Million CAD | -2354.22% |
| 2020 Q3 | -289.92 Thousand CAD | 39.05% |
| 2020 Q2 | -475.67 Thousand CAD | -547.51% |
| 2019 Q3 | -99.21 Thousand CAD | 44.11% |
| 2019 Q4 | -87 Thousand CAD | 12.3% |
| 2019 FY | -87 Thousand CAD | 78.38% |
| 2019 Q1 | -102.36 Thousand CAD | 74.56% |
| 2019 Q2 | -177.51 Thousand CAD | -73.41% |
| 2018 Q4 | -402.39 Thousand CAD | 35.77% |
| 2018 Q3 | -626.49 Thousand CAD | 42.5% |
| 2018 Q2 | -1.08 Million CAD | 29.57% |
| 2018 Q1 | -1.54 Million CAD | -27.74% |
| 2018 FY | -402.39 Thousand CAD | 66.77% |
| 2017 Q1 | -824.19 Thousand CAD | -25.96% |
| 2017 Q4 | -1.21 Million CAD | -89.72% |
| 2017 Q3 | -638.34 Thousand CAD | 12.44% |
| 2017 FY | -1.21 Million CAD | -85.08% |
| 2017 Q2 | -729.07 Thousand CAD | 11.54% |
| 2016 Q2 | -51.74 Thousand CAD | 47.57% |
| 2016 FY | -654.34 Thousand CAD | -288.45% |
| 2016 Q3 | -11.02 Thousand CAD | 78.69% |
| 2016 Q1 | -98.68 Thousand CAD | 41.42% |
| 2016 Q4 | -654.34 Thousand CAD | -5835.06% |
| 2015 Q1 | -17.72 Thousand CAD | 80.31% |
| 2015 Q4 | -168.45 Thousand CAD | -553.44% |
| 2015 Q3 | -25.77 Thousand CAD | -829.98% |
| 2015 Q2 | -2772.00 CAD | 84.36% |
| 2015 FY | -168.45 Thousand CAD | -87.16% |
| 2014 Q3 | -103.26 Thousand CAD | -1467.53% |
| 2014 Q1 | -1553.00 CAD | 2.08% |
| 2014 FY | -90 Thousand CAD | -5574.91% |
| 2014 Q4 | -90 Thousand CAD | 12.85% |
| 2014 Q2 | -6588.00 CAD | -324.21% |
| 2013 Q1 | -13.11 Thousand CAD | -353.47% |
| 2013 Q2 | -1944.00 CAD | 85.18% |
| 2013 Q3 | -1342.00 CAD | 30.97% |
| 2013 FY | -1586.00 CAD | 45.18% |
| 2013 Q4 | -1586.00 CAD | -18.18% |
| 2012 Q4 | -2893.00 CAD | 0.0% |
| 2012 Q2 | -1066.00 CAD | 85.15% |
| 2012 Q1 | -7179.00 CAD | 97.17% |
| 2012 FY | -2893.00 CAD | 98.86% |
| 2012 Q3 | - CAD | 100.0% |
| 2011 FY | -253.79 Thousand CAD | 8.11% |
| 2011 Q4 | -253.79 Thousand CAD | 77.87% |
| 2011 Q3 | -1.14 Million CAD | -678.78% |
| 2011 Q2 | -147.26 Thousand CAD | 42.89% |
| 2011 Q1 | -257.85 Thousand CAD | 6.64% |
| 2010 Q4 | -276.19 Thousand CAD | -196.21% |
| 2010 Q1 | -281.95 Thousand CAD | -30.45% |
| 2010 Q2 | -161.57 Thousand CAD | 42.7% |
| 2010 Q3 | -93.24 Thousand CAD | 42.29% |
| 2010 FY | -276.19 Thousand CAD | -27.79% |
| 2009 FY | -216.13 Thousand CAD | 38.72% |
| 2009 Q4 | -216.13 Thousand CAD | 59.62% |
| 2009 Q3 | -535.19 Thousand CAD | -745.68% |
| 2009 Q2 | -63.28 Thousand CAD | 59.69% |
| 2009 Q1 | -156.98 Thousand CAD | 55.49% |
| 2008 Q2 | -394.93 Thousand CAD | -230.76% |
| 2008 FY | -352.69 Thousand CAD | -94.48% |
| 2008 Q1 | -119.4 Thousand CAD | 34.16% |
| 2008 Q3 | -565.91 Thousand CAD | -43.29% |
| 2008 Q4 | -352.69 Thousand CAD | 37.68% |
| 2007 FY | -181.34 Thousand CAD | 23.58% |
| 2007 Q3 | -244.03 Thousand CAD | 61.37% |
| 2007 Q4 | -181.34 Thousand CAD | 25.69% |
| 2007 Q2 | -631.74 Thousand CAD | 44.19% |
| 2007 Q1 | -1.13 Million CAD | -377.05% |
| 2006 Q3 | -620.34 Thousand CAD | -4765.84% |
| 2006 Q4 | -237.29 Thousand CAD | 61.75% |
| 2006 FY | -237.29 Thousand CAD | -476.38% |
| 2006 Q2 | -12.74 Thousand CAD | 0.0% |
| 2005 FY | -41.17 Thousand CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 100.051% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 100.196% |
| SQZ Biotechnologies Company | -36.23 Million USD | 99.978% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 100.019% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 99.872% |
| Mesoblast Limited | 55.85 Million USD | 100.014% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 100.872% |
| Genus plc | 190.6 Million USD | 100.004% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 100.362% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 100.666% |
| Marizyme, Inc. | 18.56 Million USD | 100.044% |
| ContraFect Corporation | -6.02 Million USD | 99.866% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 101.189% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 106.007% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 100.7% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 100.361% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 100.147% |
| MultiCell Technologies, Inc. | 90.04 USD | 9082.674% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 98.898% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 100.062% |
| EV Biologics, Inc. | 1.36 Million USD | 100.591% |
| Q BioMed Inc. | 4.06 Million USD | 100.199% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 100.026% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 101.3% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 100.803% |
| Biomind Labs Inc. | 711.4 Thousand USD | 101.137% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 100.007% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 100.063% |
| Skye Bioscience, Inc. | -5.72 Million USD | 99.859% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 100.94% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 105.785% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 100.143% |
| IMV Inc. | 7.67 Million USD | 100.105% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 140.711% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 100.367% |
| GB Sciences, Inc. | 1.74 Million USD | 100.463% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 95.599% |
| HST Global, Inc. | 96.79 Thousand USD | 108.356% |
| CSL Limited | 10.52 Billion USD | 100.0% |
| Halberd Corporation | 144.72 Thousand USD | 105.589% |
| Enzolytics Inc. | 981.65 Thousand USD | 100.824% |
| Resverlogix Corp. | 6.45 Million USD | 100.125% |
| Affymax, Inc. | -5.59 Million USD | 99.855% |
| SYBLEU INC | 473.71 Thousand USD | 101.707% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 98.798% |
| argenx SE | -2.02 Billion USD | 100.0% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 100.019% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 99.983% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 100.299% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 99.909% |
| AVAX Technologies, Inc. | -5.9 Million USD | 99.863% |
| Zenith Capital Corp. | 10.06 Thousand USD | 180.366% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.999% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 104.035% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 100.339% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 104.916% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 100.013% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 100.405% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -2.57 Million USD | 99.685% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 102.248% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 100.04% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 55.847% |
| BioStem Technologies, Inc. | 4.47 Million USD | 100.181% |
| ONE Bio Corp. | 9.04 Million USD | 100.089% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 104.019% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -517.405% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 103.922% |
| Agentix Corp. | 37.63 Thousand USD | 121.493% |
| LadRx Corporation | -2.03 Million USD | 99.603% |
| Cell Source, Inc. | 9.23 Million USD | 100.088% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 60.368% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 101.273% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 101.273% |
| NovAccess Global Inc. | 2.17 Million USD | 100.371% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 100.114% |
| Itoco Inc. | 228.3 Thousand USD | 103.543% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 105.948% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 100.163% |
| Kadimastem Ltd | -253.1 Thousand USD | 96.804% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 102.013% |
| CytoDyn Inc. | 20.26 Million USD | 100.04% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -1150.077% |
| Mobile Lads Corp. | 484.23 Thousand USD | 101.67% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 12.735% |
| Qrons Inc. | 351.42 Thousand USD | 102.301% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 100.105% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 96.76% |
| Rebus Holdings, Inc. | 305 Thousand USD | 102.652% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 100.181% |
| International Stem Cell Corporation | 2.59 Million USD | 100.312% |
| Bioxytran, Inc. | 1.89 Million USD | 100.426% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 112.959% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 100.371% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 100.236% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 100.095% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 101.047% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 99.353% |
| Neutra Corp. | 52.18 Thousand USD | 115.498% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 99.675% |
| PureTech Health plc | -167.19 Million USD | 99.995% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 96.698% |
| IXICO plc | -4.44 Million USD | 99.818% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 100.061% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 100.015% |
| CSL Limited | 10.52 Billion USD | 100.0% |
| Cellectis S.A. | -43.81 Million USD | 99.982% |